Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Research & Development (2020 - 2025)

Mirum Pharmaceuticals has reported Research & Development over the past 6 years, most recently at $51.1 million for Q4 2025.

  • Quarterly results put Research & Development at $51.1 million for Q4 2025, up 16.08% from a year ago — trailing twelve months through Dec 2025 was $186.2 million (up 32.39% YoY), and the annual figure for FY2025 was $186.2 million, up 32.39%.
  • Research & Development for Q4 2025 was $51.1 million at Mirum Pharmaceuticals, up from $43.0 million in the prior quarter.
  • Over the last five years, Research & Development for MIRM hit a ceiling of $51.1 million in Q4 2025 and a floor of $22.0 million in Q2 2023.
  • Median Research & Development over the past 5 years was $31.4 million (2022), compared with a mean of $33.4 million.
  • Biggest five-year swings in Research & Development: surged 119.92% in 2021 and later plummeted 36.83% in 2022.
  • Mirum Pharmaceuticals' Research & Development stood at $27.8 million in 2021, then increased by 11.99% to $31.1 million in 2022, then decreased by 0.55% to $30.9 million in 2023, then skyrocketed by 42.32% to $44.0 million in 2024, then increased by 16.08% to $51.1 million in 2025.
  • The last three reported values for Research & Development were $51.1 million (Q4 2025), $43.0 million (Q3 2025), and $46.1 million (Q2 2025) per Business Quant data.